secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2021-11-12T23:59:59+00:00
Accession:  0001564590-21-056427
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 7.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD Q3 net product revenue $24.5M (+41% YoY); appoints Hugh O'Dowd CEO
--------------------------------------------------------------------------------

- CEO Robert Finizio to become Vice Chair; President Hugh O'Dowd becomes CEO effective on or before Dec 31, 2021.
- Q3 net product revenue $24.5M, up 41% YoY; ANNOVERA TRx 8,351 (+62.7% YoY).
- Net loss $47.4M ($0.11/sh) vs $32.6M ($0.12/sh) in Q3 2020; includes $7.3M severance.
- Cost savings plan to cut SG&A by $40M in 2022; additional ~$20M annualized from vitaCare divestiture.
- Manufacturing issues: ANNOVERA batch failures; supplemental NDA PDUFA date Dec 12, 2021; revenue covenant risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/0001564590-21-056427-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459021056427/txmd-8k_20211111.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-056427

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer